KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Issued
Ratios

Sarepta Therapeutics (SRPT) Other Gross PP&E Adjustments (2016 - 2025)

Sarepta Therapeutics has reported Other Gross PP&E Adjustments over the past 15 years, most recently at $500.5 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $500.5 million for Q4 2025, up 22.54% from a year ago — trailing twelve months through Dec 2025 was $500.5 million (up 22.54% YoY), and the annual figure for FY2025 was $500.5 million, up 22.54%.
  • Other Gross PP&E Adjustments for Q4 2025 was $500.5 million at Sarepta Therapeutics, up from -$158.0 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for SRPT hit a ceiling of $500.5 million in Q4 2025 and a floor of -$170.6 million in Q1 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$81.3 million (2021), compared with a mean of -$1.8 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 51.32% in 2021 and later plummeted 176.7% in 2023.
  • Sarepta Therapeutics' Other Gross PP&E Adjustments stood at $248.9 million in 2021, then grew by 1.21% to $251.9 million in 2022, then increased by 7.58% to $271.0 million in 2023, then soared by 50.74% to $408.5 million in 2024, then increased by 22.54% to $500.5 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $500.5 million (Q4 2025), -$158.0 million (Q3 2025), and -$169.7 million (Q2 2025) per Business Quant data.